Sign In
Buy INSM
$106.92
-0.490 (-0.456%)
At Close: Jul 24, 2026
Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock?
03:51am, Tuesday, 31'st Mar 2026
Insmed (INSM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
E. Ohman J or Asset Management AB Makes New $912,000 Investment in Insmed, Inc. $INSM
05:06am, Thursday, 26'th Mar 2026
E. Ohman J or Asset Management AB purchased a new stake in Insmed, Inc. (NASDAQ: INSM) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchase
Insmed CEO reveals Japan patient population exceeds US market for lung disease
10:58am, Wednesday, 25'th Mar 2026
Here is a fact that should reframe how you think about Insmed (NASDAQ:INSM) and its lung disease franchise: Japan has more patients with MAC lung disease than the entire United States.
Insmed: "Strong Buy" As Possible Label Expansion For ARIKAYCE Bodes Well
05:10pm, Tuesday, 24'th Mar 2026
Insmed (INSM) remains a "Strong Buy", driven by positive phase 3b ENCORE results for ARIKAYCE in 1st-line MAC lung disease and robust pipeline progress. INSM is positioned to expand ARIKAYCE's label t
INSM Stock Gains After Arikayce Hits Goal in Label Expansion Study
10:10am, Tuesday, 24'th Mar 2026
Insmed stock jumps as Arikayce meets key goals in a late-stage study, paving the way for label expansion and a major boost to its potential market.
Insmed Incorporated (INSM) Shareholder/Analyst Call Transcript
12:43pm, Monday, 23'rd Mar 2026
Insmed Incorporated (INSM) Shareholder/Analyst Call Transcript
Insmed Lung Infection Therapy Data Impresses, Analyst Sees Approval Path
12:24pm, Monday, 23'rd Mar 2026
The ENCORE study's results indicate that Arikayce (amikacin liposome inhalation suspension), in combination with a multidrug therapy, met its primary and all secondary endpoints, showcasing its potent
Insmed shares rise on positive late-stage trial results for lung disease therapy
10:12am, Monday, 23'rd Mar 2026
Insmed Incorporated (NASDAQ:INSM) shares jumped almost 8% in early trade on Monday after the company reported positive topline results from a Phase 3b study evaluating its lung disease therapy ARIKAY
—The Study Met Primary and All Multiplicity-Controlled Secondary Culture Conversion Endpoints, Demonstrating Statistically Significant and Clinically Meaningful Improvements in Respiratory Symptom S
506,245 Shares in Insmed, Inc. $INSM Bought by Bank of Nova Scotia
04:30am, Monday, 16'th Mar 2026
Bank of Nova Scotia purchased a new stake in shares of Insmed, Inc. (NASDAQ: INSM) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchang
Aquatic Capital Management LLC Has $10.99 Million Stake in Insmed, Inc. $INSM
03:29am, Monday, 16'th Mar 2026
Aquatic Capital Management LLC trimmed its stake in Insmed, Inc. (NASDAQ: INSM) by 61.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC)
Algert Global LLC Purchases 62,802 Shares of Insmed, Inc. $INSM
03:27am, Sunday, 15'th Mar 2026
Algert Global LLC boosted its position in shares of Insmed, Inc. (NASDAQ: INSM) by 76.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission.
Insmed Incorporated (INSM) Presents at Leerink Global Healthcare Conference 2026 Transcript
11:00am, Tuesday, 10'th Mar 2026
Insmed Incorporated (INSM) Presents at Leerink Global Healthcare Conference 2026 Transcript
Insider Selling: Insmed (NASDAQ:INSM) CEO Sells $1,562,374.97 in Stock
04:52am, Sunday, 08'th Mar 2026
Insmed, Inc. (NASDAQ: INSM - Get Free Report) CEO William Lewis sold 10,699 shares of the company's stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $146.03, fo
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Thursday, 05'th Mar 2026
BRIDGEWATER, N.J., March 5, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor
